These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 7584099

  • 1. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.
    Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT.
    Gene Ther; 1994 Sep; 1(5):332-7. PubMed ID: 7584099
    [Abstract] [Full Text] [Related]

  • 2. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
    Deshane J, Cabrera G, Grim JE, Siegal GP, Pike J, Alvarez RD, Curiel DT.
    Gynecol Oncol; 1995 Oct; 59(1):8-14. PubMed ID: 7557620
    [Abstract] [Full Text] [Related]

  • 3. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
    Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT.
    Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
    [Abstract] [Full Text] [Related]

  • 4. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.
    Jannot CB, Beerli RR, Mason S, Gullick WJ, Hynes NE.
    Oncogene; 1996 Jul 18; 13(2):275-82. PubMed ID: 8710366
    [Abstract] [Full Text] [Related]

  • 5. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 18; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 6. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis.
    Deshane J, Grim J, Loechel S, Siegal GP, Alvarez RD, Curiel DT.
    Cancer Gene Ther; 1996 Sep 18; 3(2):89-98. PubMed ID: 8729907
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.
    Brysch W, Magal E, Louis JC, Kunst M, Klinger I, Schlingensiepen R, Schlingensiepen KH.
    Cancer Gene Ther; 1994 Jun 15; 1(2):99-105. PubMed ID: 7621247
    [Abstract] [Full Text] [Related]

  • 14. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity.
    Barnes MN, Deshane JS, Siegal GP, Alvarez RD, Curiel DT.
    Clin Cancer Res; 1996 Jul 15; 2(7):1089-95. PubMed ID: 9816272
    [Abstract] [Full Text] [Related]

  • 15. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.
    Mol Pharmacol; 2008 Feb 15; 73(2):338-48. PubMed ID: 17975007
    [Abstract] [Full Text] [Related]

  • 16. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
    Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D.
    Cancer Res; 2006 Apr 01; 66(7):3764-72. PubMed ID: 16585203
    [Abstract] [Full Text] [Related]

  • 17. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy.
    Deshane J, Siegal GP, Wang M, Wright M, Bucy RP, Alvarez RD, Curiel DT.
    Gynecol Oncol; 1997 Mar 01; 64(3):378-85. PubMed ID: 9062138
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.